132 related articles for article (PubMed ID: 23393915)
1. A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis.
Buti S; Donini M; Lazzarelli S; Passalacqua R
Acta Biomed; 2012 Aug; 83(2):88-94. PubMed ID: 23393915
[TBL] [Abstract][Full Text] [Related]
2. Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.
Buti S; Donini M; Bersanelli M; Gattara A; Leonardi F; Passalacqua R
Drugs R D; 2017 Dec; 17(4):585-596. PubMed ID: 28895069
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
Makino K; Yoda K; Tomoishi J; Kume H
BMC Res Notes; 2014 Dec; 7():872. PubMed ID: 25471941
[TBL] [Abstract][Full Text] [Related]
4. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
Kondo T; Takagi T; Kobayashi H; Iizuka J; Nozaki T; Hashimoto Y; Ikezawa E; Yoshida K; Omae K; Tanabe K
Jpn J Clin Oncol; 2014 Mar; 44(3):270-7. PubMed ID: 24474815
[TBL] [Abstract][Full Text] [Related]
5. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
Najjar YG; Mittal K; Elson P; Wood L; Garcia JA; Dreicer R; Rini BI
Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
[TBL] [Abstract][Full Text] [Related]
6. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib.
Miyake H; Harada K; Miyazaki A; Fujisawa M
Med Oncol; 2015 Mar; 32(3):78. PubMed ID: 25698532
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma.
Ohzeki T; Fukasawa S; Komaru A; Namekawa T; Sato Y; Takagi K; Kobayashi M; Uemura H; Ichikawa T; Ueda T
Int J Urol; 2014 Oct; 21(10):1065-8. PubMed ID: 24930736
[TBL] [Abstract][Full Text] [Related]
8. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients.
Neri B; Vannini A; Brugia M; Muto A; Rangan S; Rediti M; Tassi R; Cerullo C
Int J Urol; 2013 May; 20(5):478-83. PubMed ID: 23113655
[TBL] [Abstract][Full Text] [Related]
9. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.
Guida FM; Santoni M; Conti A; Burattini L; Savini A; Zeppola T; Caricato M; Cascinu S; Tonini G; Santini D
Crit Rev Oncol Hematol; 2014 Dec; 92(3):208-17. PubMed ID: 25151214
[TBL] [Abstract][Full Text] [Related]
10. [Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?].
Thiery-Vuillemin A; Mouillet G; Pouessel D; Barthelemy P; Caty A; Sebbagh S; Vanno YA; Laplaige P; Cheverau C; Ravaud A
Bull Cancer; 2014 Sep; 101(9):832-40. PubMed ID: 25295955
[TBL] [Abstract][Full Text] [Related]
11. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: at least 12-month follow-up.
Zhang CJ; Zhao PJ; Li XS; Zhao J; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; He ZS; Jin J; Zhou LQ
Chin Med J (Engl); 2013; 126(15):2826-9. PubMed ID: 23924450
[TBL] [Abstract][Full Text] [Related]
13. How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.
Bracarda S; Negrier S; Casper J; Porta C; Schmidinger M; Larkin J; Gross Goupil M; Escudier B
Expert Rev Anticancer Ther; 2017 Mar; 17(3):227-233. PubMed ID: 28044472
[TBL] [Abstract][Full Text] [Related]
14. [The safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) for treatment of metastatic renal cell carcinoma].
Togo Y; Shimatani K; Hanasaki T; Yo T; Nakanishi Y; Nagasawa S; Hashimoto T; Shiraishi Y; Taoka R; Suzuki T; Go S; Higuchi Y; Kanematsu A; Nojima M; Tsuchihashi K; Makino Y; Shimizu Y; Kanamaru S; Kono Y; Matsumoto K; Utsunomiya N; Ito N; Kawakita M; Yamamoto S
Hinyokika Kiyo; 2014 May; 60(5):209-14. PubMed ID: 24894855
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and tolerability of a sunitinib 3-week administration schedule in metastatic renal cell carcinoma patients: report of three cases.
Neri B; Vannini A; Tassi R; Brugia M; Rangan S; Rediti M; Cerullo C
Oncol Res; 2012; 20(5-6):259-64. PubMed ID: 23581233
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma.
Iwamoto K; Ishihara H; Takagi T; Kondo T; Yoshida K; Iizuka J; Tanabe K
Med Oncol; 2018 Apr; 35(6):78. PubMed ID: 29687160
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience.
Ezz El Din M
Clin Genitourin Cancer; 2017 Jun; 15(3):e455-e462. PubMed ID: 28392154
[TBL] [Abstract][Full Text] [Related]
19. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
Eichelberg C; Heuer R; Chun FK; Hinrichs K; Zacharias M; Huland H; Heinzer H
Eur Urol; 2008 Dec; 54(6):1373-8. PubMed ID: 18692304
[TBL] [Abstract][Full Text] [Related]
20. Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia.
Crumbaker M; Guminski A; Gurney H; Sabanathan D; Wong S; Pavlakis N
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e45-e49. PubMed ID: 28429452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
